Erythropoiesis-Stimulating Agents: Benefits and Risks in Supportive Care of Cancer
نویسندگان
چکیده
منابع مشابه
Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer
Anemia, already common in cancer patients, is often exacerbated by chemotherapy. Cancer patients who are anemic have been shown to have a blunted response for production of endogenous erythropoietin growth factor. This anemia can be corrected with exogenous erythropoietin growth factors, of which three available are worldwide: epoetin alfa, epoetin beta, and darbepoetin alfa. Collectively, thes...
متن کاملContinuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
PURPOSE Erythropoiesis-stimulating agents (ESA) are approved for the treatment of anemia in patients with nonmyeloid malignancies whose anemia is due to the effect of concomitantly administered chemotherapy. Since the 1993 approval of epoetin alfa in patients with cancer, the risk of thrombovascular events, decreased survival, and poorer tumor control have been increasingly recognized. The risk...
متن کاملBenefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.
BACKGROUND Erythropoiesis-stimulating agents are used to treat anemia in patients with cancer. However, their safety and effectiveness is controversial. We did a systematic review of the clinical efficacy and harms of these agents in adults with anemia related to cancer or chemotherapy. METHODS We conducted a systematic review of published and unpublished randomized controlled trials (RCTs) u...
متن کاملWarning flags for erythropoiesis-stimulating agents and cancer-associated anemia.
A recent U.S. Food and Drug Administration (FDA) alert has raised further concerns about potential adverse effects of erythropoiesis-stimulating agents (ESAs) in anemic cancer patients who are not receiving chemotherapy [1]. The warning was issued following interim analysis of an investigator-led phase III trial of 989 patients with head and neck cancers randomized to receive darbepoetin alfa (...
متن کاملPharmacovigilance in practice: erythropoiesis-stimulating agents
Pharmacovigilance (PV) is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or other problems related to medical products after they have been licensed for marketing. The purpose of PV is to advance the safe use of marketed medical products. Regulatory agencies and license holders collaborate to collect data reported by health car...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Oncology
سال: 2008
ISSN: 1718-7729
DOI: 10.3747/co.2008.172